Cervical Cancer Screening Cascade for women living with HIV: a cohort study from Zimbabwe.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
2
3
2023
pubmed:
1
1
2022
medline:
1
1
2022
Statut:
ppublish
Résumé
Countries with high HIV prevalence, predominantly in sub-Sahahran Africa, have the highest cervical cancer rates globally. HIV care cascades successfully facilitated the scale-up of antiretroviral therapy. A cascade approach could similarly succeed to scale-up cervical cancer screening, supporting WHO's goal to eliminate cervical cancer. We defined a Cervical Cancer Screening Cascade for women living with HIV (WLHIV), evaluating the continuum of cervical cancer screening integrated into an HIV clinic in Zimbabwe. We included WLHIV aged ≥18 years enrolled at Newlands Clinic in Harare from June 2012-2017 and followed them until June 2018. We used a cascade approach to evaluate the full continuum of secondary prevention from screening to treatment of pre-cancer and follow-up. We report percentages, median time to reach cascade stages, and cumulative incidence at two years with 95% confidence intervals (CI). We used univariable Cox proportional hazard regressions to calculate cause-specific hazard ratios with 95% CIs for factors associated with completing the cascade stages. We included 1624 WLHIV in the study. The cumulative incidence of cervical screening was 85.4% (95% CI 83.5-87.1) at two years. Among the 396 WLHIV who received screen-positive tests in the study, the cumulative incidence of treatment after a positive screening test was 79.5% (95% CI 75.1-83.2) at two years. The cumulative incidence of testing negative at re-screening after treatment was 36.1% (95% CI 31.2-40.7) at two years. Using a cascade approach to evaluate the full continuum of cervical cancer screening, we found less-than 80% of WLHIV received treatment after screen-positive tests and less-than 40% were screen-negative at follow-up. Interventions to improve linkage to treatment for screen-positive WLHIV and studies to understand the clinical significance of screen-positive tests at follow-up among WLHIV are needed. These gaps in the continuum of care must be addressed in order to prevent cervical cancer.
Identifiants
pubmed: 36860760
doi: 10.1371/journal.pgph.0000156
pmc: PMC9974171
mid: NIHMS1852975
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Références
Lancet Glob Health. 2021 Feb;9(2):e161-e169
pubmed: 33212031
Afr J Prim Health Care Fam Med. 2015 May 05;7(1):
pubmed: 26245601
Lancet Oncol. 2010 Feb;11(2):165-73
pubmed: 20005175
Clin Infect Dis. 2019 Oct 15;69(9):1555-1565
pubmed: 30602038
Int J Gynaecol Obstet. 2021 Jan;152(1):53-59
pubmed: 33188707
J Glob Oncol. 2018 Jul;4:1-10
pubmed: 30084698
Chin Med J (Engl). 2019 Aug 5;132(15):1773-1779
pubmed: 31335474
Int J Gynaecol Obstet. 2019 Nov;147(2):246-251
pubmed: 31482577
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):257-63
pubmed: 25886932
J Clin Epidemiol. 2020 Dec;128:83-92
pubmed: 32828836
Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
pubmed: 23199964
Lancet Oncol. 2017 Dec;18(12):1665-1679
pubmed: 29126708
Pan Afr Med J. 2017 Jul 21;27:215
pubmed: 28979617
J Int AIDS Soc. 2021 Jul;24(7):e25761
pubmed: 34292649
JAMA. 2019 Oct 22;322(16):1570-1579
pubmed: 31638680
Clin Infect Dis. 2020 Dec 17;71(10):e540-e548
pubmed: 32162657
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS Med. 2021 Mar 4;18(3):e1003528
pubmed: 33661957
PLoS One. 2020 Apr 7;15(4):e0217606
pubmed: 32255796
Lancet Oncol. 2020 Jan;21(1):175-184
pubmed: 31734069
J Epidemiol Glob Health. 2020 Mar;10(1):28-35
pubmed: 32175707
N Engl J Med. 1986 Feb 20;314(8):512-4
pubmed: 3945278
Am J Obstet Gynecol. 2015 May;212(5):606.e1-8
pubmed: 25499260
Curr Opin HIV AIDS. 2016 Jan;11(1):102-8
pubmed: 26545266
Papillomavirus Res. 2019 Dec;8:100170
pubmed: 31176807
PLoS Med. 2011 May;8(5):e1001032
pubmed: 21610859
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
PLoS One. 2019 Sep 18;14(9):e0222750
pubmed: 31532808
Int J STD AIDS. 2006 Aug;17(8):507-11
pubmed: 16925893
AIDS. 2006 Nov 28;20(18):2337-44
pubmed: 17117020
Int J Cancer. 2013 Aug 1;133(3):721-9
pubmed: 23364833
AIDS. 2017 Jan 14;31(2):233-240
pubmed: 28002084